Highly reliable LFIA based on selenium nanoparticle reveals long-term real-world dynamics of neutralizing antibodies against SARS-CoV-2
Peer-Reviewed Publication
Updates every hour. Last Updated: 20-Oct-2026 10:16 ET (20-Oct-2026 14:16 GMT/UTC)
Monitoring COVID-19 NAbs dynamics remains dissolved as the lack of analytical strategies deployable in most practice, as stably remaining protein activity seems particularly difficult. We engineer selenium nanoparticles for LFIA that preserves protein activity and enhances stability. NAbs levels decrease with age and over time after infection, and they drop sharply with neurological and hematological diseases according to 1,328 samples. Our work provides a reliable and universally platform for next-generation point-of-care immunity monitoring and vaccine evaluation.
An unexpected observation by a University of Queensland researcher could lead to a new treatment for deadly infectious diseases including COVID‑19, pneumonia in infants and children, or viral infections caused by Ebola and hantavirus.
UQ neuroscientist and biochemist Dr Merja Joensuu, said the idea came while working on unrelated research.
Adults with kidney transplants who were treated for COVID-19 with the antiviral remdesivir within a week of COVID-19 diagnosis and who received at least three consecutive days of therapy were less likely than kidney transplant recipients who did not receive the antiviral to experience cardiovascular or kidney problems up to a year later, according to findings from a target trial emulation study that published in JAMA Network Open.
In a discovery that could redefine the future of cancer immunotherapy, scientists from Celloram Inc., University Hospitals and Case Western Reserve University have developed a novel cancer vaccine platform that transforms the impact of the largest immunological event in modern history – a synchronized mass immune memory generated through SARS-CoV-2 infection and vaccination – into a powerful ally against cancer.
Published today in Nature Communications, the study introduces PROTEXI, an innovative dendritic cell vaccine platform designed to harness pre-existing antiviral immune memory to amplify the body's natural ability to recognize and destroy tumors.
Contrary to what is often assumed, the polycrises – from finance to war – did not push the environment off the public agenda over the last decade – quite the opposite. In 2010, Europeans saw the economy and health as the main challenges facing their countries; by 2020, health had become the number one (in the context of COVID), but the environment also moved up and overtook some other topics, even though one might expect it to drop off the agenda in times of crisis.
Based on UK COVID Symptom Study Biobank data collected in the early years of the pandemic, experts from King’s College London and Flinders University in Australia have carried out one of the first large-scale longitudinal studies to assess the extent of residual or continuing sleep and related mental health problems, including people with 'long COVID'
A new study has found that key antiviral proteins were unable to effectively combat the coronavirus in certain patients because they harbored a large and diverse population of B cells that produced antibodies targeting the interferons themselves.
A new study in the American Journal of Public Health shows that proposed bills aiming to reduce vaccine access, weaken vaccination requirements, and increase vaccine exemptions increased dramatically in state legislatures from 2021-2023, at times exceeding the number of bills seeking to strengthen vaccine access and mandates. At least 40 percent of bills introduced in each full legislative cycle after the start of the pandemic have been antivaccine-related. Republican lawmakers sponsored 86 percent of the antivaccine bills introduced during this period. Democratic lawmakers introduced 54 percent of provaccine bills, which are bills that supported an increase in access to, or funding and promotion of, vaccines across state legislatures.
Smaller doses of COVID-19 booster vaccines can provide long-lasting immunity, helping to reduce costs and improve access to vaccination, according to new research. And the findings could also inform vaccine dosing and options during future pandemics.
A German analysis explores what underlies shifts in the timing of seasonal surges of respiratory diseases, as well as shifts in surges of heart-related deaths, that occurred after the COVID-19 pandemic began. Michael Sieber and Arne Traulsen of the Max Planck Institute for Evolutionary Biology, Germany, present these findings in the open-access journal PLOS Global Public Health on July 15, 2026.
Schoolchildren in Hong Kong face intense academic demands, with long hours of sedentary study leaving little time for movement. On average, their physical activity falls short of the World Health Organization’s recommendation of at least 60 minutes of moderate-to-vigorous physical activity (MVPA) per day.
A research team at The Education University of Hong Kong (EdUHK) has addressed this challenge by designing exercise videos and coaching materials in the aftermath of the COVID-19 pandemic. Tracking 119 primary school students and their guardians over two years, the study examined how different forms of guidance and interaction influence children’s motivation to exercise.
Findings revealed that home-based exercise videos boosted MVPA in the short term (by around 6–7 minutes), while parent support strategies grounded in Self-Determination Theory—such as offering choices, giving positive feedback, and encouraging parent-child interaction—helped sustain motivation and meet psychological needs.